Treatment options for metastatic melanoma. A systematic review

Cancer Therapy

Volumn 7, Issue ISSUE A, 2009, Pages 188-199

  Blesa, Joan Manek Gasent ^a   Pulido, Enrique Grande ^b   Pulla, Mariano Provencio ^c   Candel, Vicente Alberola ^d  

^a HOSPITAL MARINA ALTA   (Spain)

^b PFIZER INC   (United States)

^c HOSPITAL ARNAU DE VILANOVA   (Spain)

^d HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

Author keywords

Angiogenesis; DTIC; Immunotherapy; Melanoma; Treatment

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; AMIFOSTINE; AXITINIB; BEVACIZUMAB; CARBOPLATIN; CARMUSTINE; CISPLATIN; DACARBAZINE; FOTEMUSTINE; IMATINIB; INTERLEUKIN 2; IPILIMUMAB; LOMEGUATRIB; MONOCLONAL ANTIBODY LM 609; NITROSOUREA DERIVATIVE; OBLIMERSEN; PACLITAXEL; PLATINUM COMPLEX; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; SORAFENIB; TAMOXIFEN; TAXANE DERIVATIVE; TEMOZOLOMIDE; THALIDOMIDE; TICILIMUMAB; UNINDEXED DRUG; VINBLASTINE; VINCA ALKALOID; VINDESINE;

ADOPTIVE TRANSFER; APOPTOSIS; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BRAIN METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL PROLIFERATION; CHOROID MELANOMA; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DIARRHEA; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG TOLERABILITY; FATIGUE; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; HYPOPHYSITIS; IMMUNOMODULATION; LEUKOPENIA; LOW DRUG DOSE; LUNG METASTASIS; MELANOMA; METASTASIS POTENTIAL; MONOTHERAPY; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROTEIN TARGETING; REVIEW; SKIN DISEASE; SYSTEMATIC REVIEW; THROMBOCYTOPENIA;

EID: 69949166243     PISSN: 15439135     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (88)

1. Aamdal S, Wolff I, Kaplan S, Paridaens R, Kerger J, Schachter J, Wanders J, Franklin HR, Verweij J (1994) Docetaxel (Taxotere) in advanced malignant melanoma: a phase II study of the EORTC Early Clinical Trials Group. Eur J Cancer 30A(8), 1061-1064.
2. Ahmad T, Marais R, Pyle L, James M, Schwartz B, Gore M, Eisen T (2004) BAY 43-9006 in patients with advanced melanoma: the Royal Marsden experience (Abst 7506). J Clin Oncol 22 No 14S (July 15 Supplement).
3. Amaravadi R, Schucter LM, Kramer A, Barth SF, Villanueva J, Troxel AB, Tuveso DA, Nathanson KL, O'Dwyer PJ, Flaherty KT (2006) Preliminary results of a randomized Phase II study comparing two schedules of temozolomide in combination with sorafenib in patients with advanced melanoma (Abst 8009). J Clin Oncol 24 No 18S (June 20 Supplement).
4. Atkins MB, Hsu J, Lee S, Cohen GI, Flaherty LE, Sosman JA, Sondak VK, Kirkwood JM; Eastern Cooperative Oncology Group (2008) Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 26, 5748-54.
5. Atkins MB, Lee S, Flaherty LE, Sosman J. A, Sondak V K. Kirkwood JM (2003) A prospective randomized Phase III trial of concurrent biochemotherapy (BCT) with cisplatin, vinblastine, dacarbazine (CVD), IL-2 and interferon alpha-2b (IFN) versus CVD alone in patients with metastatic melanoma (E3695): An ECOG-coordinated intergroup trial (Abst 2847). Proc Am Soc Clin Oncol 22.
6. Atkins MB, O'Boyle KR, Sosman JA, Weiss GR, Margolin KA, Ernest ML, Kappler K, Mier JW, Sparano JA, Fisher RI (1994) Multiinstitutional Phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma. J Clin Oncol 12, 1553-1560.
7. Atkins MB, Sosman J, Agarwala S, Logan T., Clark J, Ernstoff M, Lawson D, Dutcher J, Weiss G,. Urba W, Margoli K (2005) A Cytokine Working Group Phase II study of temozolomide (TMZ), thalidomide (THAL) and whole brain radiation therapy (WBRT) for patients with brain metastases from melanoma (Abst 7552). J Clin Oncol 23 No 16S (June 1 Supplement).
8. Avril MF, Aamdal S, Grob JJ, Hauschild A, Mohr P, Bonerandi JJ, Weichenthal M, Neuber K, Bieber T, Gilde K, Guillem Porta V, Fra J, Bonneterre J, Saïag P, Kamanabrou D, Pehamberger H, Sufliarsky J, Gonzalez Larriba JL, Scherrer A, Menu Y (2004) Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a Phase III study. J Clin Oncol 22, 1118-1125.
9. Avril MF, Bonneterre J, Delaunay M, Grosshans E, Fumoleua P, Israel L, Bugat R, Namer M, Cupissol D, Kerbrat P (1990) Combination chemotherapy of dacarbazine and fotemustine in disseminated malignant melanoma. Experience of the French Study Group. Cancer Chemother Pharmacol 27, 81-84.
10. Bafaloukos D, Aravantinos G, Fountzilas G, Stathopoulos G, Gogas H, Samonis G, Briasoulis E, Mylonakis N, Skarlos DV, Kosmidis P (2002) Docetaxel in combination with dacarbazine (DTIC) in patients with advanced melanoma. Oncology 63, 333-337.
11. Balch CM, Reintgen DS, Kirkwood JM (1997) Cutaneous melanoma. In: DeVita VT Jr, Hellman S, Rosenber SA, eds. Cancer: Principles and Practice of Oncology. 5th ed. Philadelphia, Pa: Lippincott-Raven; pp. 1947-1994.
12. Bedikian AY, Millward M, Pehamberger H, Conry R, Gore M, Trefzer U, Pavlick AC, DeConti R, Hersh EM, Hersey P, Kirkwood JM, Haluska FG; Oblimersen Melanoma Study Group (2006) Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol 24, 4738-4745.
13. Bedikian AY, Weiss GR, Legha SS, Burris HA 3rd, Eckardt JR, Jenkins J, Eton O, Buzaid AC, Smetzer L, Von Hoff DD (1995) Phase II trial of docetaxel in patients with advanced cutaneous malignant melanoma previously untreated with chemotherapy. J Clin Oncol 13, 2859-2899.
14. Blansfield JA, Beck KE, Tran K, Yang JC, Hughes MS, Kammula US, Royal RE, Topalian SL, Haworth LR, Levy C, Rosenberg SA, Sherry RM (2005) Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. J Immunother 28, 593-598.
15. Boaziz C, Breau JL, Morere JF, Israël R (1991) Brain metastases of malignant melanomas. Bull Cancer 78, 347-353.
16. Buzaid AC, Legha S, Winn R, Belt R, Pollock T, Wiseman C, Ensign LG (1993) Cisplatin (C), Vinblastine (V), and Dacarbazine (D) (CVD) versus dacarbazine alone in metastatic melanoma: preliminary results of a Phase II Cancer Community Oncology Program (CCOP) trial (Abst 389). Proc Am Soc Clin Oncol 12.
17. Calabresi F, Aapro M, Becquart D, Dirix L, Wils J, Ardizzoni A, Gerard B (1991) Multicenter Phase II trial of the single fotemustine in patients with advanced malignant melanoma. Ann Oncol 2, 377-378.
18. Chapman PB, Einhorn LH, Meyers ML, Saxman S, Destro AN, Panageas KS, Begg CB, Agarwala SS, Schuchter LM, Ernstoff MS, Houghton AN, Kirkwood JM (1999) Phase III multicenter randomized trial of Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 17, 2745-2751.
19. Coates AS, Segelov E (1994) Long term response to chemotherapy in patients with visceral metastatic melanoma. Ann Oncol 5, 249-251.
20. Cocconi G, Bella M, Calabresi F, Tonato M, Canaletti R, Boni C, Buzzi F, Ceci G, Corgna E, Costa P, (1992) Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen. N Engl J Med 327, 516-523.
21. Costanza ME, Nathanson L, Schoenfeld D, Wolter J, Colsky J, Regelson W, Cunningham T, Sedransk N (1977) Results with methyl-CCNU and DTIC in metastatic melanoma. Cancer 40, 1010-1015.
22. Costanzi JJ, Vaitkevicius VK, Quagliana JM, Hoogstraten B, Coltman CA Jr, Delaney FC (1975) Combination chemotherapy for disseminated malignant melanoma. Cancer 35, 342-346.
23. Curtin JA, Busam K, Pinkel D, Bastian BC (2006) Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 24, 4340-4346.
24. Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, Cho KH, Aiba S, Bröcker EB, LeBoit PE, Pinkel D, Bastian BC (2005) Distinct sets of genetic alterations in melanoma. N Engl J Med 353, 2135-2147.
25. Danson S, Lorigan P, Arance A, Clamp A, Ranson M, Hodgetts J, Lomax L, Ashcroft L, Thatcher N, Middleton MR (2003) Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma. J Clin Oncol 21, 2551-2557.
26. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA. (2002) Mutations of the BRAF gene in human cancer. Nature 417, 949-954.
27. Del Prete SA, Maurer LH, O'Donnell J (1984) Combination chemotherapy with cisplatin, carmustine, dacarbazine and tamoxifen in metastatic melanoma. Cancer Treat Rep 68, 1403-1405.
28. Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U, Robbins PF, Huang J, Citrin DE, Leitman SF, Wunderlich J, Restifo NP, Thomasian A, Downey SG, Smith FO, Klapper J, Morton K, Laurencot C, White DE, Rosenberg SA (2008) Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 26, 5233-5339.
29. Eggermont AM, Kirkwood JM (2004) Re-evaluating of the role of dacarbazine in metastatic melanoma: what have we learned in 30 years? Eur J Cancer 40, 1825-1836.
30. Eggermont AMM (2006) Reaching first base in the treatment of metastatic melanoma [editorial]. J Clin Oncol 24, 4673.
31. Einzig AI, Hochster H, Wiernik PH, Trump DL, Dutcher JP, Garowski E, Sasloff J, Smith TJ (1991) A Phase II study of Taxol in patients with malignant melanoma. Invest New Drugs 9, 59-64.
32. Eisen T, Ahmad T, Flaherty KT, Gore M, Kaye S, Marais R, Gibbens I, Hackett S, James M, Schuchter LM, Nathanson KL, Xia C, Simantov R, Schwartz B, Poulin-Costello M, O'Dwyer PJ, Ratain MJ (2006) Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br J Cancer 95, 581-586.
33. Eton O, Legha SS, Bedikian AY, Lee JJ, Buzaid AC, Hodges C, Ring SE, Papadopoulos NE, Plager C, East MJ, Zhan F, Benjamin RS (2002) Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a Phase III randomized trial. J Clin Oncol 20, 2045-2052.
34. Evans LM, Casper ES, Rosenbluth R (1987) Participating community oncology program investigators: Phase II trial of carboplatin in advanced malignant melanoma. Cancer Treat Rep 71, 171-172.
35. Falkson CI, Falkson G, Falkson HC (1991) Improved results with the addition of interferon alfa-2b to dacarbazine in the treatment of patients with metastatic malignant melanoma. J Clin Oncol 9, 1403-1408.
36. Falkson CI, Ibrahim J, Kirkwood JM, Coates AS, Atkins MB, Blum RH (1998) Phase III trial of dacarbazine versus dacarbazine with tamoxifen versus dacarbazine with interferon alfa-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol 16, 1743-1751.
37. Fischkoff SA, Hersh E, Weber J, Powderly J, Khan K, Pavlick A, Samlowski W, O'Day S, Nichol G, Yellin M (2005) Durable responses and long-term progression-free survival observed in a Phase II study of MDX-010 alone or in combination with dacarbazine (DTIC]) in metastatic melanoma (Abst 7525). Proc Am Soc Clin Oncol 23, 716S.
38. Flaherty KT, Brose M, Schucter L, D. Tuveson D, Lee R, Schwartz B, Lathia C, Weber B, O'Dwyer P (2004) Phase I/II trial of BAY 43-9006, carboplatin (C) and paclitaxel (P) demonstrates preliminary antitumor activity in the expansion cohort of patients with metastatic melanoma (Abst 7507). J Clin Oncol 22 No 14S (July 15 Supplement).
39. Flaherty LE, Robinson W, Redman BG, Gonzalez R, Martino S, Kraut M, Valdivieso M, Rudolph AR. (1993) A Phase II study of dacarbazine and cisplatin in combination with outpatient administered interleukin-2 in metastatic malignant melanoma. Cancer 71, 3520-3525.
40. Fletcher WS, Green S, Fletcher JR, Dana B, Jewell W, Townsend RA (1988) Evaluation of cis-platinum and DTIC combination chemotherapy in disseminated melanoma. A Southwest Oncology Group Study. Am J Clin Oncol 11, 589-593.
41. Fruehauf JP, Lutzky J, McDermott CK, Brown CK, Pithavala YK, Bycot Wt, Shalinsky D, Liau KF, A. Niethammer A, O. Rixe O (2008) Axitinib (AG-013736) in patients with metastatic melanoma: a phase II study (Abstr 9006). J Clin Oncol 26 (May 20 Supplement).
42. Glover D, Glick JH, Weiler C, Fox K, Guerry D (1987) WR-2721 and high-dose cisplatin: an active combination in the treatment of metastatic melanoma. J Clin Oncol 5, 574-578.
43. Glover D, Ibrahim J, Kirkwood J, Glick J, Karp D, Stewart J, Ewell M, Borden E; Eastern Cooperative Oncology Group (2003) Phase II randomized trial of cisplatin and WR-2721 versus cisplatin alone for metastatic melanoma: an Eastern Cooperative Oncology Group Study (E1686). Melanoma Res 13, 619-626.
44. Hersey P, Sosman J, O'Day S, J. Richards J, Bedikian A,. Gonzalez R, Sharfman W, R. Weber R, Logan T, Kirkwood JM (2005) A Phase II, randomized, open-label study evaluating the antitumor activity of MEDI-522, a humanized monoclonal antibody directed against the human metastatic melanoma (MM) (Abst 7507). J Clin Oncol 23 No 16S (June 1 Supplement).
45. Hersh E, O'Day S, Gonzalez R, Ribas A, Samlowski W, Gordon M (2006) Phase II trial of ABI-007 (Abraxane) in previously treated and chemotherapy naive patients with metastatic melanoma (Abst ABS-0141). Melanoma Res 16, S78.
46. Hersh EM, Weber JJ, Powderly J, Yellin M, Kahn K, Pavlick A, Samlowski W, Nichol G, O'Day S (2004) A Phase II, randomized multi-center study of MDX-010 alone or in combination with dacarbazine (DTIC) in stage IV metastatic malignant melanoma (Abst 7511). J Clin Oncol 22 No 14S (July 15 Supplement).
47. Hodi FS, Soiffer RJ, Clark J, Finkelstein DM, Haluska FG (2002) Phase II study of paclitaxel and carboplatin for malignant melanoma. Am J Clin Oncol 25, 283-286.
48. Hwu WJ, Krown SE, Menell JH, Panageas KS, Merrell J, Lamb LA, Williams LJ, Quinn CJ, Foster T, Chapman PB, Livingston PO, Wolchok JD, Houghton AN (2003) Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma. J Clin Oncol 21, 3351-3356.
49. Hwu WJ, Lis E, Menell JH, Panageas KS, Lamb LA, Merrell J, Williams LJ, Krown SE, Chapman PB, Livingston PO, Wolchok JD, Houghton AN (2005) Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II study. Cancer 103, 2590-2597
50. Jacquillat C, Khayat D, Banzet P, Weil M, Fumoleau P, Avril MF, Namer M, Bonneterre J, Kerbrat P, Bonerandi JJ (1990) Final report of the French multicentric Phase II study of the nitrosurea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases. Cancer 66, 1873-1878.
51. Jaissle GB, Ulmer A, Henke-Fahle S, Fierlbeck G, Bartz-Schmidt KU, Szurman P (2008) Suppression of melanoma-associated neoangiogenesis by bevacizumab. Arch Dermatol 144, 525-527.
52. Karasarides M, Chiloeches A, Hayward R, Niculescu-Duvaz D, Scanlon I, Friedlos F, Ogilvie L, Hedley D, Martin J, Marshall CJ, Springer CJ, Marais R (2004) B-RAF is a therapeutic target in melanoma. Oncogene 23, 6292-6298.
53. Keilholz U, Conradt C, Legha SS, Khayat D, Scheibenbogen C, Thatcher N, Goey SH, Gore M, Dorval T, Hancock B, Punt CJ, Dummer R, Avril MF, Bröcker EB, Benhammouda A, Eggermont AM, Pritsch M (1998) Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients. J Clin Oncol 16, 2921-2929.
54. Keilholz U, Goey SH, Punt CJ, Proebstle TM, Salzmann R, Scheibenbogen C, Schadendorf D, Liénard D, Enk A, Dummer R, Hantich B, Geueke AM, Eggermont AM (1997) Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group. J Clin Oncol 15, 2579-2588.
55. Keilholz U, Punt CJ, Gore M, Kruit W, Patel P, Lienard D, Thomas J, Proebstle TM, Schmittel A, Schadendorf D, Velu T, Negrier S, Kleeberg U, Lehman F, Suciu S, Eggermont AM (2005) Dacarbazine, cisplatin and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized Phase III trial (18951) of the European Organization for Research and Treatment of Cancer Melanoma Group. J Clin Oncol 23, 6747-6755.
56. Kirkwood JM, Agarwala S (1993) Systemic cytotoxic and biologic therapy melanoma. In: DeVita VT, Hellman S, Rosenberg SA, eds. PPO Updates. Vol 7. Philadelphia, Pa: Lippincott; 1.
57. Kleeberg UR, Engel E, Israels P, Bröcker EB, Tilgen W, Kennes C, Gérard B, Lejeune F, Glabbeke MV, Lentz MA (1995) Palliative therapy of melanoma patients with fotemustine. Inverse relationship between tumour load and treatment effectiveness. A multicenter Phase II trial of the EORTC Melanoma Cooperative Group (MCG). Melanoma Res 5, 195-200.
58. Lattanzi SC, Tosteson T, Chertoff J, Maurer LH, O'Donnell J, LeMarbre PJ, Mott L, DelPrete SA, Forcier RJ, Ernstoff MS (1995) Dacarbazine, cisplatin and carmustine, with or without tamoxifen, for metastatic melanoma: 5-year followup. Melanoma Res 5, 365-369.
59. Lee SM, Thatcher N, Margison GP (1991) O6-alkylguanine-DNA alkyltrasferase depletion and regeneration in human peripheral lymphocytes following dacarbazine and fotemustine. Cancer Res 51, 619-623.
60. Legha SS, Ring S, Eton O, Bedikian A, Buzaid AC, Plager C, Papadopoulos N (1998) Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma. J Clin Oncol 16, 1752-1759.
61. Legha SS, Ring S, Eton O, Bedikian A, Buzaid AC, Plager C, Papadopoulos N (1998) Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma. J Clin Oncol 16, 1752-1759.
62. Legha SS, Ring S, Papadopoulos N, Plager C, Chawla S, Benjamin R (1989) A prospective evaluation of a triple-drug regimen containing cisplatin, vinblastine and dacarbazine (CVD) for metastatic melanoma. Cancer 64, 2024-2029.
63. Lens MB, Reiman T, Husain AF (2003) Use of tamoxifen in the treatment of malignant melanoma. Systematic review and metaanalysis of randomized controlled trial. Cancer 98, 1355-1361.
64. Lutzky J, Nunez Y, Graham P (2006) A Phase II trial of oxaliplatin in patients with advanced melanoma (Abst 18016). J Clin Oncol 24 No 18S (June 20 Supplement).
65. Middleton MR, Grob JJ, Aaronson N, Fierlbeck G, Tilgen W, Seiter S, Gore M, Aamdal S, Cebon J, Coates A, Dreno B, Henz M, Schadendorf D, Kapp A, Weiss J, Fraass U, Statkevich P, Muller M, Thatcher N (2000) Randomized Phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 18, 158-166.
66. Miller AJ, Mihm MC Jr (2006) Melanoma. N Engl J Med 355, 51-65.
67. Mitjans F, Meyer T, Fittschen C, Goodman S, Jonczyk A, Marshall JF, Reyes G, Piulats J (2000) In vivo therapy of malignant melanoma by means of antagonists of aV integrins. Int J Cancer 87, 716-723.
68. Mohammed MQ, Retsas S (2000) Oxaliplatin is active in vitro against human melanoma cell lines: comparison with cisplatin and carboplatin. Anticancer Drugs 11, 859-863.
69. Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, Royal RE, Topalian SL, Kammula US, Restifo NP, Zheng Z, Nahvi A, de Vries CR, Rogers-Freezer LJ, Mavroukakis SA, Rosenberg SA (2006) Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314, 126-129.
70. Newlands ES, Blackledge GR, Slack JA, Rustin GJ, Smith DB, Stuart NS, Quarterman CP, Hoffman R, Stevens MF, Brampton MH (1992) Phase I trial of temozolomide (CCR 81045: M&B 39831: NSC 362856). Br J Cancer 65, 287-291.
71. O'Day SJ, Gammon G, Boasberg PD, Martin MA, Kristedja TS, Guo M, Stern S, Edwards S, Fournier P, Weisberg M, Cannon M, Fawzy NW, Johnson TD, Essner R, Foshag LJ, Morton DL (1999) Advantages of concurrent biochemotherapy modified by decrescendo interleukin-2, granulocyte colony-stimulating factor and tamoxifen for patients with metastatic melanoma. J Clin Oncol 17, 2752-2761.
72. Plummer R, Lorigan P, Evans J, Steven N, Middleton M, Wilson R, Snow K, Dewji R, Calvert H (2006) First and final report of a Phase II study of the poly-(ADP-ribosed) polymerase (PARR) inhibitor, AGO14699 in combination with temozolomide (TMZ) in patients with metastatic malignant melanoma (MM) (Abst 8013). J Clin Oncol 24 No 18S (June 20 Supplement).
73. Quagliana JM, Stephens RL, Baker LH, Costanzi JJ (1984) Vindesine in patients with metastatic malignant melanoma. A Southwest Oncology Group study. J Clin Oncol 4, 316-319.
74. Rao RD, Holtan SG, Ingle JN, Croghan GA, Kottschade LA, Creagan ET, Kaur JS, Pitot HC, Markovic SN (2006) Combination of paclitaxel and carboplatin as second-line therapy for patients with metastatic melanoma. Cancer 106, 375-382.
75. Ribas A, Camacho LH, Lopez-Berestein G, Pavlov D, Bulanhagui CA, Millham R, Comin-Anduix B, Reuben JM, Seja E, Parker CA, Sharma A, Glaspy JA, Gomez-Navarro J (2005) Antitumor activity in melanoma and anti-self responses in a Phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J Clin Oncol 23, 8968-8977.
76. Ribas A, Hauschild A, Kefford R, Punt J, Haanen JB, Marmol M, Garbe C, Gomez-Navarro J, Pavlov D, Marshall M (2008) Phase III, open label, randomized, comparative study of tremelimumab (CP-675,206) and chemotherapy (TMZ or DTIC) in patients with advanced melanoma (abstr LBA9011). J Clin Oncol 26 (May 20 Supplement).
77. Rosenberg SA, Dudley ME (2004) Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. Proc Natl Acad Sci U S A 101(Suppl 2), 14639-14645.
78. Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Seipp CA, Einhorn JH, White DE, Steinberg SM (1999) Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b. J Clin Oncol 17, 968-975.
79. Rusthoven JJ, Quirt IC, Iscoe NA, McCulloch PB, James KW, Lohmann RC, Jensen J, Burdette-Radoux S, Bodurtha AJ, Silver HK, Verma S, Armitage GR, Zee B, Bennett K (1996) Randomized, double-blind placebo-controlled trial comparing the response rates of carmustine, dacarbazine and cisplatin with and without tamoxifen in patients with metastatic melanoma. J Clin Oncol 14, 2083-2090.
80. Sato T, Eschelman DJ, Gonsalves CF, Terai M, Chervoneva I, McCue PA, Shields JA, Shields CL, Yamamoto A, Berd D, Mastrangelo MJ, Sullivan KL (2008) Immunoembolization of malignant liver tumors, including uveal melanoma, using granulocyte-macrophage colony-stimulating factor. J Clin Oncol 26, 5436-4542.
81. Solit DB, Garraway LA, Pratilas CA, Sawai A, Getz G, Basso A, Ye Q, Lobo JM, She Y, Osman I, Golub TR, Sebolt-Leopold J, Sellers WR, Rosen N (2006) BRAF mutation predicts sensitivity to MEK inhibition. Nature 439, 358-362.
82. Strumberg D, Richly H, Hilger RA, Schleucher N, Korfee S, Tewes M, Faghih M, Brendel E, Voliotis D, Haase CG, Schwartz B, Awada A, Voigtmann R, Scheulen ME, Seeber S (2005) Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 23, 965-972.
83. Tawbi H, Tarhini A, Moschos S, Sulecki M, Viverette F, Radkowski R, Shipe-Spotloe J,. Kunkel C, Rae M, Kirkwood J (2006) Phase I trial of lomeguatrib (PN) combined with dacarbazine (DTIC) for treatment of patients with melanoma and other solid tumors: initial results (Abst 8016). J Clin Oncol 24 No 18S (June 20 Supplement).
84. Tchekmedyian S, Glasby J, Korman A, Keler T, Deo Y, Davis TA (2002) MDX-010 (human anti-CTLA4): a Phase I trial in malignant melanoma (Abst 56). Proc Am Soc Clin Oncol 21.
85. Vorobiof DA, Sarli R, Falkson G (1986) Combination chemotherapy with dacarbazine and vindesine in the treatment of metastatic malignant melanoma. Cancer Treat Rep 70, 927-928.
86. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64, 7099-7109.
87. Wyman K, Atkins MB, Prieto V, Eton O, McDermott DF, Hubbard F, Byrnes C, Sanders K, Sosman JA (2006) Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy. Cancer 106, 2005-2011.
88. Zimpfer-Rechner C, Hofmann U, Figl R, Becker JC, Trefzer U, Keller I, Hauschild A, Schadendorf D (2003) Randomized phase II study of weekly paclitaxel versus paclitaxel and carboplatin as second-line therapy in disseminated melanoma: a multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG). Melanoma Res 13, 531-536.